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BSTRACT
Background:
 
Interleukin (IL)-18 acts as both a Th1
and Th2 cytokine, but its association with allergic dis-
eases remains unclear. The aim of the present study
was to measured plasma IL-18 and serum IgE levels in
atopic children to evaluate how IL-18 is associated
with allergic diseases.
 
Methods:
 
The plasma IL-18 and serum IgE levels in
51 atopic children, 28 healthy control children and 14
healthy control adults were measured by enzyme-
linked immunosorbent assay (ELISA). The 5
 
′
 
 end of the
IL-18 gene of 48 atopic children and 20 healthy
control children was sequenced.
 
Results:
 
The plasma IL-18 level was significantly ele-
vated in children with bronchial asthma and/or atopic
dermatitis. Plasma IL-18 levels in the moderate or
severe atopic dermatitis group were significantly
higher than those in either the control group or the
mild atopic dermatitis group. There was a positive cor-
relation between plasma IL-18 and serum IgE levels.
Three allelic combinations of polymorphisms in the
IL-18 gene promoter region were observed. There was
no significant difference in the plasma IL-18 levels
between groups carrying these genotypes. However,
bronchial asthma patients had significantly higher fre-
quencies of the –137 G/G genotype than did control
children.
 
Conclusions:
 
The plasma IL-18 level was elevated,
particularly in patients with atopic dermatitis. As the
clinical severity of atopic dermatitis increased, the
plasma IL-18 level also tended to increase. These find-
ings suggest that IL-18 may be associated with the
severity of atopic dermatitis.
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I
 
NTRODUCTION
 
Interleukin (IL)-18, originally known as an interferon
(IFN)-
 
γ
 
-inducing factor (IGIF), is a recently cloned
cytokine secreted by Kupffer cells of the liver and activated
macrophages.
 
1
 
 Interleukin-18 strongly enhances IFN-
 
γ
 
production by T cells, natural killer cell cytotoxicity and
T cell proliferation. Moreover, recent studies have dem-
onstrated that IL-12, which is also known as an IFN-
 
γ
 
-
inducing factor, and IL-18 exert a synergistic effect on
IFN-
 
γ
 
 production by T cells.
 
2,3
 
Interleukin-18 is a proinflammatory cytokine. Its
increased production was observed in the acute phase of
experimental autoimmune encephalomyelitis (EAE)
 
4
 
 and
antibodies to IL-18 could prevent EAE in Lewis rats.
 
5
 
In humans, IL-18 expression has been observed in Th1-
mediated chronic inflammatory diseases, such as Crohn’s
disease,
 
6
 
 rheumatoid arthritis
 
7
 
 and acute infectious
mononucleosis.
 
8
 
 Increased serum or plasma IL-18 levels
have been observed in severe melioidosis,
 
9
 
 hemo-
phagocytic lymphohistiocytosis
 
10
 
 and multiple sclerosis.
 
11
 
Increased IL-18 levels in cerebral spinal fluid have
been observed in bacterial meningitis
 
12
 
 and multiple
sclerosis.
 
11
 
However, how IL-18 is associated with allergic dis-
eases remains unclear. We have reported previously that
the serum IgE level was negatively correlated with IFN-
 
γ
 
production by phytohemagglutinin (PHA)-stimulated
peripheral blood mononuclear cells (PBMC).
 
13
 
 The IFN-
 
γ
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production by IL-12-stimulated PBMC in the atopic group
was lower than that in the control group and the serum
IgE level was negatively correlated with IFN-
 
γ
 
 production
by IL-12-stimulated PBMC.
 
14
 
 One of the reasons for this
was that reduced IFN-
 
γ
 
 production following IL-12 stimu-
lation was associated with heterozygous IL-12R
 
β
 
2 muta-
tions in atopic patients.
 
15
 
 The presence of abnormalities
not only in the IL-12, but also in the IL-18, signal trans-
duction pathway could be assumed in atopic patients.
However, recently there have been some reports that
IL-18 is also associated with Th2 reactions.
 
16–19
 
 Nakan-
ishi 
 
et al
 
. reviewed the dual regulatory roles of IL-18 in the
immune system; that is, IL-18 regulates not only the Th1
pathway, but also the Th2 pathway.
 
20
 
In the present study, we found a correlation between
the plasma IL-18 level and the severity of atopic derma-
titis in children.
 
M
 
ETHODS
 
Patients and control subjects
 
All patients and healthy volunteers were recruited from
the Department of Pediatrics, Gifu University School of
Medicine, and informed consent was obtained from all
subjects or their parents. Fifty-one children with allergic
diseases, particularly atopic dermatitis and bronchial
asthma, 28 healthy control children and 14 healthy
control adults were studied. Seventeen patients had
bronchial asthma only (eight patients were in the no
asthma attack phase, nine patients were in the asthma
attack phase), 18 patients had atopic dermatitis only
and 16 patients had both bronchial asthma and atopic
dermatitis. The diagnosis of atopic dermatitis was made
according to the criteria of Hanifin,
 
21
 
 whereas that of
bronchial asthma was made according to the criteria
of  the American Thoracic Society.
 
22
 
 The severity of
atopic dermatitis was evaluated based on the criteria
of Rajka and Langeland.
 
23
 
 The serum IgE levels, age
and sex of the study subjects are listed in Table 1. The
healthy controls did not have a history of atopic diseases
and their serum IgE levels were within normal limits for
their age. They were healthy and free of acute infection
at the time of testing.
 
Plasma and cell preparation
 
Plasma and leukocytes were separated from the
heparinized blood of control donors and patients. All
plasma samples were stored at –30
 
°
 
C until assay.
 
Interleukin-18 assay
 
Plasma IL-18 levels were measured with a human IL-18
enzyme-linked immunosorbent assay (ELISA) kit (Medical
& Biological Laboratories, Nagoya, Japan); the lower
detection limit was 12.5 pg/mL.
 
IgE assay
 
Plasma or serum IgE levels were determined by chemi-
luminescent enzyme immunoassay. Plasma IgE values
were regarded as serum IgE levels. Specific IgE anti-
bodies for house dust, 
 
Dermatophagoides
 
, hen egg and
cows’ milk were measured with a fluoroenzyme immuno-
assay by means of a Uni-Cap assay kit (Pharmacia,
Uppsala, Sweden). Scores of 3+ to 6+ were considered
positive.
 
Sequencing of the 5
 
′
 
 end of the IL-18 gene
 
Genomic DNA was extracted from leukocytes using a
SepaGene (Sanko Junyaku, Tokyo, Japan). A 1492 bp
fragment of the IL-18 gene was amplified by polymerase
chain reaction (PCR) using primers 5
 
′
 
-TTGATCCCACT-
TCGTGCTTTCA-3
 
′
 
 and 5
 
′
 
-CCTTTCCTCTTCCCGAA-
GCTGT-3
 
′
 
. Conditions for the PCR were 40 cycles of
94
 
°
 
C for 1 min, 64
 
°
 
C for 1 min and 72
 
°
 
C for 2 min.
DNA was purified using geneclean II (BIO 101,
Carlsbad, CA, USA) and used for big dye terminator
bidirectional sequencing (Applied Biosystems, Foster
 
Table 1
 
Subject characteristics
Control Bronchial 
asthma
Atopic 
dermatitis
Atopic dermatitis +
bronchial asthmaAdults Children
No. subjects 14 28 17 18 16
Age (years) 33.9 
 
± 
 
9.4 4.8 
 
± 
 
4.4 8.1 
 
± 
 
4.1 4.9 
 
± 
 
4.6 5.1 
 
± 
 
3.8
Sex (males/females) 5/9 16/12 14/3 13/5 10/6
IgE (IU/mL) 8–140 5–110 24–2400 11–11 000 18–5400
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City, CA, USA). Primers 5′-CCCTTCCTAGCAAAG-
TAATAC-3′, 3′-GAATAATCAGTCCTATTGGGG-5′, 5′-
CCAATAGGACTGATTATTCCGCA-3′ and 3′-AGGAG-
GGCAAAATGCACTGG-5 were used for sequencing an
approximate 700 bp fragment upstream of the known
IL-18 cDNA sequence. For the position –607 specific
PCR, a common reverse primer 5′-TAACCTCATTCAG-
GACTTCC-3′ and two sequence-specific forward primers
5′-GTTGCAGAAAGTGTAAAAATTATTAC-3′ and 5′-
GTTGCAGAAAGTGTAAAAATTATTAA-3′ were used. For
the position –137 specific PCR, a common reverse
primer 5′-AGGAGGGCAAAATGCACTGG-3′ and two
sequence-specific forward primers 5′-CCCCAACTTT-
TACGGAAGAAAAG-3′ and 5′-CCCCAACTTTTACG-
GAAGAAAAC-3′ were used. Each PCR was performed
with rTaq (Takara Shuzo, Shiga, Japan) and the condi-
tions for PCR were 40 cycles of 94°C for 1 min, 64°C
for 1 min and 72°C for 1 min. Products separated by
2% agarose gel electrophoresis were visualized by stain-
ing with ethidium bromide.
Statistical analyses
The significance of differences between two groups was
analyzed by the Mann–Whitney U-test. The significance
of differences between multiple groups was evaluated
by  the Kruskal–Wallis test and further analysis was
performed by the Bonferroni/Dunn test. Spearman’s
correlation coefficient (R) was used to calculate the
correlation between two variables. The frequencies of
alleles were compared through the use of χ2 statistics.
Statistical significance was assumed for P < 0.05.
RESULTS
Mean (± SD) plasma IL-18 levels in patients with allergic
diseases (394 ± 20 pg/mL), healthy control adults
(201 ± 79 pg/mL) and control children (174 ± 87 pg/
mL) are shown in Fig. 1a. We found significantly higher
levels of plasma IL-18 in patients with allergic diseases
(P < 0.0001) than in healthy control children. There was
no significant difference in plasma IL-18 levels between
healthy control adults and healthy control children.
In the present study, we particularly investiaged bron-
chial asthma and atopic dermatitis as representative
allergic diseases in children. Mean (± SD) plasma IL-18
levels in patients with bronchial asthma (324 ± 122 pg/
mL), atopic dermatitis (508 ± 238 pg/mL) and atopic
dermatitis and bronchial asthma (338 ± 236 pg/mL)
are shown in Fig. 1b. We found significantly higher
levels of plasma IL-18 in the bronchial asthma group
(P < 0.0001), the atopic dermatitis group (P < 0.0001)
and the atopic dermatitis and bronchial asthma group
(P = 0.0023) compared with healthy control children.
Furthermore, the plasma IL-18 level of the atopic derma-
titis group was particularly high. The atopic dermatitis
group has significantly higher levels of plasma IL-18 than
the bronchial asthma group (P = 0.01). There was no
significant difference in plasma IL-18 levels between the
Fig. 1 (a) Comparison of plasma interleukin (IL)-18 levels in
control adults, control children and children with allergic
disease. Plasma IL-18 levels in children with allergic disease
were significantly higher than those in healthy control children.
(b) Comparison of plasma IL-18 levels in control children and
children with bronchial asthma, atopic dermatitis and atopic
dermatitis plus bronchial asthma. Plasma IL-18 levels in chil-
dren with bronchial asthma, atopic dermatitis and atopic
dermatitis plus bronchial asthma were significantly higher than
those of healthy control children.
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acute phase (323 ± 153 pg/mL) and non-acute phase of
asthma (325 ± 85 pg/mL).
Figure 2a,b shows the plasma IL-18 and serum IgE
levels of each group classified according to the severity of
atopic dermatitis with or without bronchial asthma.23
Using the Kruskal–Wallis test, we found significant differ-
ences in levels of plasma IL-18 (P < 0.0001) and serum
IgE (P < 0.0001) between groups of patients classified
according to the severity of atopic dermatitis. Further
analysis using the Bonferroni/Dunn test was performed
for comparisons among groups. Plasma IL-18 levels in
the moderate or severe atopic dermatitis group were
significantly higher than those in either the control group
or the  mild atopic dermatitis group. Serum IgE levels in
the severe atopic dermatitis group were significantly
higher than those in the other groups and serum IgE
levels in the mild and moderate atopic dermatitis groups
were significantly higher than those in the control group.
Figure 2c shows the relationship between plasma IL-18
and serum IgE levels in healthy controls and patients.
It was reported that serum IL-18 levels in Nc/Nga mice
tended to be negatively correlated with serum IgE
levels24 but, in the present study, there was a positive cor-
relation between plasma IL-18 and serum IgE levels
(R = 0.472; P < 0.0001). Three patients (P1, P2, P3)
had higher plasma IL-18 levels more than the control
group + 2SD, but their serum IgE levels were within
normal limits for their age. These three patients were also
negative for specific IgE.
We analyzed the 5′ end of the IL-18 gene sequence in
48 allergic patients and 20 healthy control children. Five
single-nucleotide polymorphisms were detected. Two are
located in the 5′-untranslated region of the IL-18 gene
and three are located in the promoter region. Three
allelic combinations of the polymorphisms observed in
the Japanese populations were the same as those found
in the Swedish population25 (Table 2). Figure 3 shows the
Fig. 2 (a) Relationship between plasma interleukin (IL)-18
levels and severity of atopic dermatitis. Plasma IL-18 levels in the
moderate or severe atopic dermatitis group were significantly
higher than those in the control group or mild atopic dermatitis
group (mild (n = 14) 257 ± 95.9 pg/mL; moderate (n = 12)
549 ± 226 pg/mL; severe (n = 8) 595 ± 302 pg/mL). (b) Rela-
tionship between serum IgE levels and the severity of atopic
dermatitis. Serum IgE levels in the severe atopic dermatitis group
were significantly higher than those in the other groups and
serum IgE levels in the mild and moderate atopic dermatitis
groups were significantly higher than those in the control
group (mild (n = 14) 1320 ± 3030 IU/mL; moderate (n = 12)
1250 ± 1660 IU/mL; severe (n = 8) 5020 ± 3600 IU/mL).
(c) Relationship between plasma IL-18 levels and serum IgE
levels in healthy controls and patients. Plasma IL-18 levels were
significantly and positively correlated with serum IgE levels
(R = 0.472; P < 0.0001). Arrows indicate patients with high
plasma IL-18 levels, but low serum total IgE levels; they were
also negative for specific IgE (patient 1, patient 2, patient 3).
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plasma IL-18 levels of children with different combina-
tions of alleles. Children with the genotype 1/1 and 1/3
showed a relatively higher mean level of plasma IL-18
(1/1, 365 ± 246 pg/mL; 1/3, 408 ± 282 pg/mL). How-
ever, there was no significant difference between these
groups (P = 0.3596). Table 3 shows genotype frequen-
cies of the IL-18 promoter region in allergic patients and
healthy control children. There were no significant differ-
ences. Further analysis was performed for comparisons
among allergic patients and healthy control children at
position –137 of the IL-18 promoter region. Table 4
shows the frequencies of single nucleotide polymorphism
–137 G/C of the IL-18 promoter region in allergic
patients and healthy control children. Bronchial asthma
patients had significantly higher frequencies of the –137
G/G genotype than did control children.
DISCUSSION
Interleukin-18 was initially identified as a strong inducer
of a Th1-mediated cytokine, IFN-γ, and this function is
synergistically performed with IL-12.26 Moreover, IgE
suppression had been thought as the result of IFN-γ
induction by IL-18 because the serum IgE level was
negatively correlated with the amount of IFN-γ secreted
by the PBMC of atopic patients.13 However, it was
reported that IL-18 levels in the sera of adult patients
and in atopic dermatitis model mice (Nc/Nga) were
elevated.24 In the present study, we showed that the
plasma IL-18 levels increased significantly in children
with allergic diseases, particularly atopic dermatitis.
Tanaka et al. reported that the serum IL-18 level may
reflect asthma disease activity,27 but we found no signif-
icant difference in plasma IL-18 levels between the acute
and non-acute phases of asthma in the present study. In
contrast with patients with bronchial asthma, the plasma
IL-18 levels of patients with atopic dermatitis tended to
increase as the severity of the disease increased.
Table 2 Ploymorphisms at the 5′ end of the interleukin-18
gene
Position 
–656 –607 –137 +113 +127
Allele 1 G C G T C
Allele 2 T A C G T
Allele 3 T A G T C
Fig. 3 Relationship between levels of plasma interleukin (IL)-
18 and genotypes of the 5′ end of IL-18 gene polymorphisms in
atopic patients and healthy control children. There was no sig-
nificant difference (P = 0.3596) between these groups (1/1
(n = 14) 365 ± 246 pg/mL; 1/2 (n = 8) 252 ± 121 pg/mL;
1/3 (n = 21) 408 ± 282 pg/mL; 2/2 (n = 0); 2/3 (n = 7)
267 ± 143 pg/mL; 3/3 (n = 18) 336 ± 217 pg/mL).
Table 3 Genotype frequencies in 48 allergic patients and
20 healthy control children
Genotype Control Allergic patients
1/1 2 12
1/2 4 4
1/3 7 14
2/2 0 0
2/3 3 4
3/3 4 14
P 0.3559
Table 4 Frequencies of single nucleotide polymorphism –137 G/C of the interleukin-18 promoter region in patients and healthy
control children
Genotype Control 
(n = 20)
Allergy 
(n = 48)
Bronchial asthma 
(n = 14)
Atopic dermatitis 
(n = 18)
Atopic dermatitis + 
bronchial asthma 
(n = 16)
G/G 13 40 14 15 11
G/C 7 8 0 3 5
C / C0 0 0 0 0
P 0.0967 0.0130 0.2000 0.8125
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Why is the IL-18 level elevated particularly in patients
with bronchial asthma and severe and moderate atopic
dermatitis? One of the possible reasons is the association
with lipopolysaccharide (LPS) or endotoxin. Jorgensen
et al. reported that, in leukocytes from patients with
atopic dermatitis, bacteria and endotoxin induce the
release of basophil histamine.28 Recently, it was reported
that endotoxemia was associated with elevations in the
plasma IL-18 level in infections after acute lung injury.29
Seki et al. reported that IL-18 secretion is mediated by
activation of endogenous caspase-1 without de novo
protein synthesis after stimulation with LPS.30 El-Mezzein
et al. reported an increase in the secretion level of IL-18
by LPS-stimulated PBMC of patients with bronchial
asthma or atopic dermatitis.31 Therefore, LPS and endo-
toxin could be associated with caspase-1 activity and
IL-18 secretion in atopic dermatitis.
The second possible reason is differences in IL-18
promoter activity among IL-18-producing cells in the
patients. Vilmantas et al. reported that alleles 1 and 3 of
IL-18 promoter region polymorphisms showed a higher
transcriptional activity than allele 2, as determined by
luciferase assay using transfected human HeLa 229 cells
that were stimulated with phorbol myristate acetate and
ionomicin.25 A change from C to A at position –607
disrupts a potential cAMP-responsive element binding
protein binding site. A change from G to C at position
–137 changes the H4TF-1 nuclear factor binding site to a
binding site for an unknown factor found in the granulo-
cyte–macrophage colony stimulating factor promoter.25
In the present study, children with the genotype 1/1 and
1/3 showed a relatively higher average level of plasma
IL-18, but the association of plasma IL-18 level with poly-
morphisms of IL-18 promoter alleles and their frequen-
cies was not significant. However, the –137 G/G
genotype had a significantly higher frequency in bron-
chial asthma patients than in control children. Therefore
although the number of subjects is too small to conclu-
sively determine the association between plasma IL-18
and these polymorphisms, we can speculate that alleles 1
and 3, which had G at position –137 of the IL-18 pro-
moter region, may affect the allergy state through IL-18.
Another possibility is the existence of abnormalities in
the signal transduction pathway of IL-18. Matsui et al.
reported that IL-12Rβ2 mutations resulted in a decrease
of IFN-γ production.15 Similarly, Shikano et al. reported
that, in several atopic patients, IFN-γ production was not
induced sufficiently by IL-18, but it was induced suffi-
ciently by phytohemagglutinin or IL-12.32 In our recent
study on the IL-18 receptor, 950delCAG in the IL-18Rα
chain cDNA was found to be associated with reduced
IFN-γ production and a high serum IgE level in atopic
patients.33 Mühl et al. reported that IFN-γ upregulated the
expression of IL-18 binding protein, which is an inhibitor
of IL-18 activity, suggesting a negative feedback mecha-
nism between IL-18 and IFN-γ.34 Therefore, abnormali-
ties of IL-18 signal transduction to IFN-γ production and
the impairment of the negative feedback mechanism may
induce the increase in plasma IL-18 levels.
How is IL-18 associated with exacerbation of atopic
dermatitis? Atopic dermatitis is a chronic inflammatory
skin disease, with remissions and exacerbations. It is
generally known that serum IgE levels are elevated in
80% of patients with atopic dermatitis35,36 and the severity
of atopic dermatitis highly correlates with the levels of
serum IgE.35 In the present study, as the clinical severity
of atopic dermatitis increased, the serum IgE and plasma
IL-18 levels tended to increase. Moreover, the plasma
IL-18 levels were significantly correlated with serum IgE
levels. Yoshimoto et al. showed that, in the presence of
IL-3, IL-18 induces basophils and mast cells to release
large amounts of Th2 cytokines both in vitro and in vivo.18
Moreover, IL-18 alone has the capacity to induce IgE
accumulation in vivo.18,19 Therefore, IL-18 may be associ-
ated with allergic diseases, particularly atopic dermatitis
exacerbation through IgE production.
It is interesting that three patients (P1, P2, P3) had high
plasma IL-18 levels, but low serum total IgE levels; they
were also negative for specific IgE. In fact, many allergic
patients have low serum total IgE levels and specific IgE
levels. It has been reported that 20% of atopic dermatitis
patients with typical eczema have normal serum IgE
levels.21,37 Yoshimoto et al. reported that IL-18 could
directly stimulate histamine release by basophils.18
Recently, Tsutsui et al. also reported that keratinocyte-
caspase-1 transgenic/signal transducers and activators
of transcription (STAT) 6-deficient mice developed atopic
dermatitis without IgE production and their serum IL-18
levels were high.38 Moreover, Yagi et al. recently reported
that STAT6-deficient NC/Nga mice showed development
of atopic dermatitis, although these mice failed to
produce IgE and IL-18 had been highly expressed at the
skin lesions.39 Interleukin-18 may participate in atopic
dermatitis exacerbation by histamine production from
basophils or mast cells without IgE production.
In the present study, we found that the plasma IL-18
level was elevated in children with bronchial asthma
and atopic dermatitis. The plasma IL-18 level showed a
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positive correlation with serum IgE levels. Furthermore,
we showed that the plasma IL-18 level correlated with the
clinical severity of atopic dermatitis. Interleukin-18 has
dual roles in the Th1/Th2 system depending on condi-
tions, such as the existence of antigens or other cytokines,
including IL-10.40 Further studies of cytokine profiles in
allergic diseases and analysis of gene polymorphisms of
IL-18 and IL-18-related molecules (IL-18Rα, IL-18Rβ,
MyD88, IL-1 receptor-associated kinase (IRAK), TNF
receptor-associated factor (TRAF) 6) are important in
order to clarify the association of IL-18 with atopic
diseases.41–43
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